Baricitinib Combination Therapy Demonstrates Significant Improvement in Cardiac Conduction Defects in Rapidly Progressive Systemic Sclerosis: A Case Report
{{output}}
Objective: To evaluate the efficacy of baricitinib in combination therapy for managing refractory, rapidly progressive systemic sclerosis (SSc) with severe cardiac conduction defects and interstitial lung disease (ILD). ... ...
